Form 4: Adaptimmune Therapeutics PLC: Chief Medical Officer Acquires Options

Elliot Norry, Chief Medical Officer of Adaptimmune Therapeutics PLC, reports acquisition of options to purchase ordinary shares.

Summary

• On February 20, 2025, Elliot Norry, the Chief Medical Officer of Adaptimmune Therapeutics PLC, filed a Form 4.
• The filing reports the acquisition of options to purchase 1,612,032 ordinary shares at an exercise price of $0.1 and 1,074,696 ordinary shares at an exercise price of $0.0013.
• The options are exercisable starting February 20, 2026, with varying installment schedules and expiration dates.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of option grants to a key executive. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of options by a key executive could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biopharmaceutical industry.

Comparison to Industry Standards

• Option grants are a standard component of executive compensation packages in the biotechnology industry, used to align management's interests with those of shareholders.
• Companies like Gilead Sciences, Amgen, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The acquisition of options by the Chief Medical Officer could be viewed positively by shareholders as it aligns their interests with the company's success.

Key Dates

Keywords

Adaptimmune Therapeutics, Elliot Norry, Form 4, options, ordinary shares, Chief Medical Officer, acquisition